Kyushu University Academic Staff Educational and Research Activities Database
List of Presentations
Tadamasa Yoshitake Last modified date:2021.07.16

Lecturer / Department of Clinical Radiology, Graduate School of Medical Sciences, Kyushu University / Radiology / Kyushu University Hospital

1. Tadamasa Yoshitake, Saiji Ohga, Satoshi Nomoto, Toshihiro Yamaguchi, Kaori Asai, Hidenari Hirata, Osamu Hisano, Yushi Motomura, Akio Hiwatashi, Koji Yoshimoto, Hiroshi Honda, High pre-treatment neutrophil-to-lymphocyte ratio predicts poor survival in patients with glioblastoma treated with radiotherapy and temozolomide, ASTRO2016, 2016.09.
2. 吉武 忠正, Incidence of radiation pneumonitis after multiple courses of stereotactic body radiation therapy for lung cancer patients, ASTRO, 2014.09.
3. Tadamasa Yoshitake, Yoshiyuki Shioyama, Katsumasa Nakamura, Tomonari Sasaki, Ohga Saiji, Hideki Hirata, Hiroshi Honda, Stereotactic body radiation therapy for primary lung cancers which were clinically diagnosed without pathological confirmation: a single-institution experience, RSNA, 2012.11, Purpose
Pathological diagnosis of small lung lesions is sometimes difficult in inoperable patients. The purpose of the present study was to evaluate the outcome of stereotactic body radiotherapy (SBRT) for small lung lesions that are clinically diagnosed as primary lung cancer without pathologic confirmation.

Materials and methods
Between April 2003 and July 2011, 82 patients with small pulmonary lesions clinically diagnosed as primary lung cancer were treated with SBRT in Kyushu University Hospital. The median age of the 66 patients was 75 years (range 51- 92 years). Forty four patients were male, and 38 were female. The median tumor size was 19 mm (range 8-40 mm). Thin-section CT findings for these pulmonary lesions showed solid nodules and ground-glass opacity (GGO) nodules in 53 and 29 patients, respectively. The radiation dose was 48 Gy in 4 fractions in all patients.

Median follow-up was 20 months (range 6-83 months). Recurrence was observed in 13 (15.9%) patients (local failure, 6; regional failure, 5; distant metastases, 6) with solid nodules. There was no recurrence in 29 patients with GGO nodules. Two patients died of recurrence and 10 patients died from other diseases. Local control rate, cause-specific survival and overall survival at 3 years were 88%, 98% and 79%, respectively. Two (2.4%) patients and 5 (6.1%) patients had grade 2 radiation pneumonitis and grade 2 rib fracturing, respectively. There were no adverse effects of grade 3 or greater during follow-up.

SBRT is to be considered a safe and effective treatment option for small lung lesions clinically diagnosed as primary lung cancer without pathologic confirmation, especially in patients with GGO nodules.